Shield Therapeutics plc (LON:STX – Get Free Report) shares were down 44.5% on Tuesday. The company traded as low as GBX 2.93 and last traded at GBX 3.05. 41,407,309 shares changed hands during mid-day trading, an increase of 1,606% from the average daily volume of 2,427,170 shares. The stock had previously closed at GBX 5.50.
Shield Therapeutics Stock Performance
The business’s 50-day simple moving average is GBX 5.28 and its two-hundred day simple moving average is GBX 7. The company has a quick ratio of 2.16, a current ratio of 0.75 and a debt-to-equity ratio of -146.28. The firm has a market cap of £32.76 million, a price-to-earnings ratio of -3.05 and a beta of 1.77.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
- Republic Services Has the Momentum, But Waste Management Has Another Advantage
- Alphabet’s Golden Dome Talks Could Open a New Market, But How Much Is at Stake?
- Tempus AI Surges on Earnings Beat, But Can the Rally Last?
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
